Showing 5,401 - 5,420 results of 82,039 for search '(( 50 ((teer decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 2 we decrease ))', query time: 1.21s Refine Results
  1. 5401

    Tunable Electrical Properties of Embossed, Cellulose-Based Paper for Skin-like Sensing by Tongfen Liang (9601461)

    Published 2020
    “…By embossing such paper, its porosity decreases while its conductivity increases. Tuning the porosity of composite paper alters the magnitude and trend of conductivity over a spectrum of concentrations of conductive particles. …”
  2. 5402

    Tunable Electrical Properties of Embossed, Cellulose-Based Paper for Skin-like Sensing by Tongfen Liang (9601461)

    Published 2020
    “…By embossing such paper, its porosity decreases while its conductivity increases. Tuning the porosity of composite paper alters the magnitude and trend of conductivity over a spectrum of concentrations of conductive particles. …”
  3. 5403

    Effect of V3, MPER and IDR peptides on ID50 neutralization titers of the cross-neutralizing plasma in depletion and competition experiments. by Raiees Andrabi (138046)

    Published 2012
    “…</p>b<p><b>ID<sub>50</sub> fold decrease</b>; Plasma ID50 fold decrease for depletion assay was calculated as, ID50 with mock depleted plasma/ID50 with V3, MPER and IDR depleted plasma, and for competition assay as ID50 with untreated plasma/ID50 with V3, MPER and IDR treated plasma. …”
  4. 5404
  5. 5405
  6. 5406
  7. 5407

    Supplementary Material for: Kidney and cardiovascular outcomes in older population with mildly to moderately decreased kidney function - A nationwide cohort study by Jeon J. (10323467)

    Published 2024
    “…Introduction: Although the prevalence of chronic kidney disease (CKD) is increasing in the aging population, the clinical relevance of the CKD definition (glomerular filtration rate [GFR] < 60 ml/min/1.73 m2) in older populations remains debatable. We investigated the clinical outcomes in older populations with mildly to moderately decreased GFR (45–59 ml/min/1.73 m2, CKD stage 3A). …”
  8. 5408
  9. 5409
  10. 5410
  11. 5411
  12. 5412
  13. 5413

    NARS2 homodimerization and RNA level: effect of the p.Val213Phe and p.Asn381Ser mutations. by Mariella Simon (711384)

    Published 2015
    “…Due to high passage number, we could not measure the mt-tRNA<sup>Asn</sup> levels in the fibroblast of patient II.3.…”
  14. 5414

    datasheet1_Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.pdf by Victor Gustavo Balera Brito (9626207)

    Published 2020
    “…<p>Periodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). …”
  15. 5415

    datasheet1_Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.pdf by Victor Gustavo Balera Brito (9626207)

    Published 2020
    “…<p>Periodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). …”
  16. 5416

    datasheet1_Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.pdf by Victor Gustavo Balera Brito (9626207)

    Published 2020
    “…<p>Periodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). …”
  17. 5417
  18. 5418
  19. 5419
  20. 5420